Novel Risk Markers and Risk Assessments for Cardiovascular Disease
- 6 January 2017
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation Research
- Vol. 120 (1), 133-149
- https://doi.org/10.1161/circresaha.116.309955
Abstract
The use of risk markers has transformed cardiovascular medicine, exemplified by the routine assessment of troponin, for both diagnosis and assessment of prognosis in patients with chest pain. Clinical risk factors form the basis for risk assessment of cardiovascular disease and the addition of biochemical, cellular, and imaging parameters offers further refinement. Identifying novel risk factors may allow greater risk stratification and a steady, but gradual progression toward precision medicine. Indeed, the generation of data in this area of research is explosive and when combined with new technologies and techniques provides the potential for more refined, targeted approaches to cardiovascular medicine. Although discussing the most recent developments in this field, this review article aims to strike a balance between novelty and validity by focusing on recent large sample-size studies that have been validated in a separate cohort in most cases. Risk markers related to atherosclerosis, thrombosis, inflammation, cardiac injury, and fibrosis are introduced in the context of their pathophysiology. Rapidly developing new areas, such as assessment of micro-RNA, are also explored. Subsequently the prognostic ability of these risk markers in coronary artery disease, heart failure, and atrial fibrillation is discussed in detail.Keywords
This publication has 100 references indexed in Scilit:
- Inflammation in Atrial FibrillationJournal of the American College of Cardiology, 2012
- C-Reactive Protein, Fibrinogen, and Cardiovascular Disease PredictionThe New England Journal of Medicine, 2012
- Improving the Primary Prevention of Cardiovascular Events by Using Biomarkers to Identify Individuals With Silent Heart DiseaseJournal of the American College of Cardiology, 2012
- Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studiesThe Lancet, 2012
- Growth differentiation factor 15 deficiency protects against atherosclerosis by attenuating CCR2-mediated macrophage chemotaxisThe Journal of Experimental Medicine, 2011
- Circulating CD31+/Annexin V+ microparticles correlate with cardiovascular outcomesEuropean Heart Journal, 2010
- Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humansEuropean Heart Journal, 2010
- Thrombopoietin regulates c-Myb expression by modulating micro RNA 150 expressionExperimental Hematology, 2008
- Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosisProceedings of the National Academy of Sciences of the United States of America, 2008
- MicroRNA-133 controls cardiac hypertrophyNature Medicine, 2007